Antihyperglycemics (meglitinides)
- Short-acting insulin secretagogues
- Repaglinide/nateglinide target meal glucose
- Dose with meals; skip if meal skipped
- Less prolonged hypoglycemia than sulfonylureas
- Still cause hypoglycemia + weight gain
- Repaglinide has important CYP/OATP DDIs
- Now niche drugs rather than default therapy
Class at a glance
- Short-acting insulin secretagogues
Practical pearls
- Less prolonged hypoglycemia than sulfonylureas
Pharmacology
- Repaglinide has important CYP/OATP DDIs
Members / distinctions
- Repaglinide/nateglinide target meal glucose
- Dose with meals; skip if meal skipped
- Now niche drugs rather than default therapy
Other practical pearls
- Still cause hypoglycemia + weight gain
Self-check
- Which meglitinide has important CYP/OATP interactions?
Repaglinide.
- What clinically distinguishes repaglinide among meglitinides?
Important CYP/OATP DDIs.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
